Although NAM is not an ideal drug candidate itself, our findings suggest that targeting this novel reversible regulation mechanism of key proteins is a viable strategy in anti-TB drug development, as inhibitors of histone deacetylase have been approved for cancer treatment43. The gene discussed is STAC3; the disease is tuberculosis.